Abstract
The last four decades have ushered in substantial progress in reducing the burden of cardiovascular mortality. However, much of this improvement has been achieved through advances in managing already established disease. There is now an unprecedented opportunity to focus efforts on the primary prevention of cardiovascular events, given breakthroughs in lifestyle counseling, risk assessment, risk factor management, and pharmacotherapy. In parallel with these developments, the budding specialty known as “preventive cardiology” has come to the fore from the background of long-established clinical services such as lipid, hypertension, diabetes, and general cardiology clinics. Given the ominous projections of increased cardiovascular mortality, due to the burgeoning epidemics of obesity and diabetes, there is now a mandate to invest in cardiovascular disease prevention. This chapter focuses on the origins of preventive cardiology as a concept and as a discipline, the organization and personnel required for practice of this medical art, core competencies, common referrals to preventive cardiology programs, a suggested structure for education and fellowship training, and the need for professional recognition and board certification.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–e528.
Shapiro MD, Fazio S. Setting the agenda for preventive cardiology. Circ Res. 2017;121(3):211–3.
Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2014;383(9921):999–1008.
Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J 3rd. Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55:33–50.
Dawber TR, Moore FE, Mann GV. Coronary heart disease in the Framingham study. Am J Public Health Nations Health. 1957;47(4 Pt 2):4–24.
Castelli WP, Anderson K, Wilson PWF, Levy D. Lipids and risk of coronary heart disease The Framingham Study. Ann Epidemiol. 1992;2(1):23–8.
He Y, Lam TH, Li LS, Li LS, He SF, Liang BQ. Triglyceride and coronary heart disease mortality in a 24-year follow-up study in Xi’an, China. Ann Epidemiol. 2004;14(1):1–7.
Knuiman MW, Vu HT. Prediction of coronary heart disease mortality in Busselton, Western Australia: an evaluation of the Framingham, national health epidemiologic follow up study, and WHO ERICA risk scores. J Epidemiol Community Health. 1997;51(5):515–9.
Caerphilly and Speedwell collaborative heart disease studies. The Caerphilly and Speedwell Collaborative Group. J Epidemiol Community Health. 1984;38(3):259–62.
Truett J, Cornfield J, Kannel W. A multivariate analysis of the risk of coronary heart disease in Framingham. J Chronic Dis. 1967;20(7):511–24.
Scandinavian Simvastatin Survival Study G. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–9.
Dunn SP, Birtcher KK, Beavers CJ, Baker WL, Brouse SD, Page RL 2nd, et al. The role of the clinical pharmacist in the care of patients with cardiovascular disease. J Am Coll Cardiol. 2015;66(19):2129–39.
Tisdale JE, Jaynes HA, Kingery JR, Overholser BR, Mourad NA, Trujillo TN, et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2014;7(3):381–90.
Snider M, Kalbfleisch S, Carnes CA. Initial experience with antiarrhythmic medication monitoring by clinical pharmacists in an outpatient setting: a retrospective review. Clin Ther. 2009;31(6):1209–18.
Warden BA, Shapiro MD, Fazio S. The role of the clinical pharmacist in a preventive cardiology practice. Ann Pharmacother. 2019;53(12):1214–9.
Kaufman TM, Duell PB, Purnell JQ, Wojcik C, Fazio S, Shapiro MD. Application of PCSK9 inhibitors in practice: challenges and opportunities. Circ Res. 2017;121(5):499–501.
Kaufman TM, Warden BA, Minnier J, Miles JR, Duell PB, Purnell JQ, et al. Application of PCSK9 inhibitors in practice. Circ Res. 2019;124(1):32–7.
Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. J Clin Lipidol. 2015;9(2):129–69.
Kovacs RJ, Birtcher KK, Tisdale JE. Pharmacists and cardiologists in the ACC. J Am Coll Cardiol. 2019;74(3):470–2.
Smith SC Jr, Bittner V, Gaziano JM, Giacomini JC, Pack QR, Polk DM, et al. COCATS 4 task force 2: training in preventive cardiovascular medicine. J Am Coll Cardiol. 2015;65(17):1754–62.
Pack QR, Keteyian SJ, McBride PE, Weaver WD, Kim HE. Current status of preventive cardiology training among United States cardiology fellowships and comparison to training guidelines. Am J Cardiol. 2012;110(1):124–8.
Shapiro MD, Maron DJ, Morris PB, Kosiborod M, Sandesara PB, Virani SS, et al. Preventive cardiology as a subspecialty of cardiovascular medicine: JACC council perspectives. J Am Coll Cardiol. 2019;74(15):1926–42.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Shapiro, M.D., Fazio, S. (2021). Preventive Cardiology as Specialized Medical Art. In: Wong, N.D., Amsterdam, E.A., Toth, P.P. (eds) ASPC Manual of Preventive Cardiology. Contemporary Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-030-56279-3_29
Download citation
DOI: https://doi.org/10.1007/978-3-030-56279-3_29
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-56278-6
Online ISBN: 978-3-030-56279-3
eBook Packages: MedicineMedicine (R0)